Math Model Extensions for Thermoregulation
Certainty: 0.30. The dual-oscillator model (ch09:Dual-Oscillator Decoupling: Central SCN vs Peripheral Vascular Oscillator in Thermoregulatory Circadian Failure) can be formalized as a coupled ODE system with central SCN oscillator phase M_s(t) and peripheral vascular oscillator phase M_p(t) linked via endothelin-1 concentration ET(t). The internal phase error Δφ = |M_p - M_s| determines the degree of hypothalamic error correction demand, driving fatigue accumulation. Key prediction: reducing ET-1 (via bosentan or glycine) re-synchronizes oscillators and reduces Δφ from above 6h (ME/CFS) to below 2h. No ME/CFS ET-1-oscillator coupling data; model is speculative.
Certainty: 0.25. The vasomotor constriction bias hypothesis (ch10:Tonic Cutaneous Vasoconstriction Bias Explains Dual Heat+Cold Intolerance) can be modeled as a bistable perfusion system where constriction state C(t) and dilation state D(t) compete, with a bias parameter shifting equilibrium toward constriction. In ME/CFS (bias = +0.4), the model predicts blunted perfusion responses to both heat (ΔP decreased 70%) and cold (decreased 60%). Bias reduction via clonidine or ET-1 antagonism restores vasomotor dynamic range. No ME/CFS vasomotor modeling data. Falsified if measured laser Doppler perfusion responses in ME/CFS deviate from model predictions by more than 25% for both heat and cold challenges, indicating the bistable bias model does not capture the underlying vascular physiology.
Certainty: 0.25. For patients whose heat intolerance is predominantly seasonal (summer), a pre-season protocol combining ET-1 reduction (glycine 3 g/day + magnesium glycinate 400 mg/day), slow-paced breathing (6 breaths/min, 10 min, 3x/day), and thermal pacing education (log exposures, grade activity) may reduce heat-triggered PEM without requiring sauna access. The breathing component provides vagal tone support; the supplements address ET-1-mediated vasoconstriction; pacing prevents overload. Falsifiable: summer-intolerant protocol over 3 months reduces heat-triggered PEM episodes by >50% compared to the previous summer. No ME/CFS seasonal protocol data.
Certainty: 0.25. For patients with predominant winter cold intolerance, graded cold adaptation (20°C → 16°C ambient over 8 weeks, 3x/week), L-carnitine (2 g/day for BAT fatty acid oxidation), and magnesium glycinate (400 mg/day for vascular tone) may improve cold tolerance. Falsifiable: winter-tolerant protocol over 8 weeks increases cold tolerance by Δ3°C and reduces winter PEM frequency by >30%. No ME/CFS winter-specific protocol data; BAT activity declines with age regardless of supplementation.
Certainty: 0.30. Rural or mobility-limited patients lack access to sauna or pool facilities. A fully remote protocol — video-guided slow breathing education (10 min, 2x/day), sleep temperature optimization guidance (18–20°C bedroom), and mail-order glycine (3 g/day) — provides three thermoregulatory support mechanisms at minimal cost with no facility requirement. Weekly 15-minute telehealth check-ins support adherence. Falsifiable: telehealth protocol over 8 weeks produces >70% of in-person Waon therapy benefit with >80% adherence. No ME/CFS telehealth thermal protocol data.
Certainty: 0.25. Pregnant ME/CFS patients are excluded from pharmacological thermal interventions (bosentan teratogenic, clonidine safety unestablished). A pregnancy-safe combination of slow breathing (safe throughout pregnancy), tepid bath (35–36°C, avoiding core temperature rise above 37.5°C), magnesium glycinate (200–300 mg/day), and glycine (2–3 g/day) provides thermoregulatory support using interventions with established pregnancy safety profiles. Falsifiable: pregnancy-safe protocol over 2nd and 3rd trimesters reduces thermoregulatory symptom exacerbation by >25% versus standard care. No ME/CFS pregnancy thermal data; individual components have pregnancy safety evidence.
Certainty: 0.30. Pediatric ME/CFS requires age-appropriate thermal protocols. Low-intensity Waon (55–58°C, 10 min, 2x/week, parent-supervised), child-friendly “balloon breathing” (5 min, 2x/day), age-adjusted magnesium glycinate (4–6 mg/kg/day), and parent pacing education provide accessible thermal support for the younger demographic where BAT is more likely to be active and autonomic recovery potential is higher. Falsifiable: pediatric protocol over 8 weeks improves school attendance by >20% and reduces thermoregulatory symptom frequency by >30%. No pediatric ME/CFS thermal data.
ME/CFS and POTS have >80% comorbidity, but their thermoregulatory failure mechanisms may differ: POTS involves microvascular denervation (reduced perivascular sympathetic innervation) while ME/CFS adds mitochondrial reserve deficit, HSP70 depletion, and ET-1 elevation. If both components contribute, single-mechanism therapy (e.g., Waon alone or citrulline alone) should achieve only partial symptom improvement (40–50%), while combined therapy (Waon + citrulline + breathing) should achieve >70%. Falsifiable: ME/CFS-POTS patients show additive benefit from dual-component therapy versus single-component; isolated POTS patients respond fully to vasodilator support alone. No comparative ME/CFS vs POTS thermal phenotyping data.